Clinical Trial Update: Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B [Phase 3]

View source ↗

Summary

This Phase 3 trial compares the safety, immunogenicity, and reactogenicity of an MPL-adjuvanted recombinant hepatitis B vaccine to Engerix-B. The trial status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Engerix-B (hepatitis B vaccine)
• MPL-adjuvanted recombinant Hepatitis B vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B | Phase 3 | Status: COMPLETED